|
Market Closed -
Nasdaq
21:00:00 09/02/2026 GMT
|
5-day change
|
1st Jan Change
|
|
62.64 USD
|
-2.91%
|
 |
-9.65%
|
-5.65%
|
|
01-13 |
Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026
|
CI
| |
01-06 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $2,534,661, According to a Recent SEC Filing
|
MT
| |
12-30 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $527,100, According to a Recent SEC Filing
|
MT
| |
12-30 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $3,575,575, According to a Recent SEC Filing
|
MT
| |
12-22 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $5,443,462, According to a Recent SEC Filing
|
MT
| |
04/09/25 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $375,000, According to a Recent SEC Filing
|
MT
| |
15/04/25 |
Arrowhead Pharmaceuticals Names Daniel Apel Chief Financial Officer
|
MT
| |
15/04/25 |
Arrowhead Pharmaceuticals Says Ken Myszkowski To Retire As CFO
|
RE
| |
14/04/25 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,533,337, According to a Recent SEC Filing
|
MT
| |
17/03/25 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $774,975, According to a Recent SEC Filing
|
MT
| |
07/02/25 |
Arrowhead Pharmaceuticals, Inc. Appoints Douglas Ingram as Director
|
CI
| |
03/02/25 |
Genelux Names Matthew Pulisic as CFO
|
MT
| |
23/12/24 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,486, According to a Recent SEC Filing
|
MT
| |
18/12/24 |
Arrowhead Pharmaceuticals, Inc. Announces Retirement of Douglass Given as Director, Effective December 31, 2024
|
CI
| |
26/11/24 |
Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors
|
CI
| |
30/10/24 |
Carisma Therapeutics Announces Changes to Its Board of Directors
|
CI
| |
22/02/24 |
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024
|
CI
| |
02/02/24 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,860,019, According to a Recent SEC Filing
|
MT
| |
22/01/24 |
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024
|
CI
| |
08/01/24 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $292,804, According to a Recent SEC Filing
|
MT
| |
08/01/24 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,910, According to a Recent SEC Filing
|
MT
| |
22/12/23 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $342,480, According to a Recent SEC Filing
|
MT
| |
22/11/23 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,315, According to a Recent SEC Filing
|
MT
| |
30/10/23 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $589,223, According to a Recent SEC Filing
|
MT
| |
21/09/23 |
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,624,223, According to a Recent SEC Filing
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
